HUTCHMED (China) (HCM) Intangibles (2014 - 2025)

HUTCHMED (China) (HCM) posted quarterly Intangibles of $8.9 million for Q4 2025, down 7.32% quarter-over-quarter from $9.6 million in Q2 2025.

HUTCHMED (China) (HCM) Intangibles (2014 - 2025) Analysis & Trends

HUTCHMED (China) (HCM) has reported Intangibles for 11 consecutive years, with $8.9 million the latest figure, recorded in Q4 2025.

In Q4 2025, Intangibles changed N/A year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $8.9 million (changed N/A YoY), while the FY2025 annual figure was $8.9 million, changed N/A from the prior year.
Intangibles slipped to $8.9 million in Q4 2025 per HCM's latest filing, from $9.6 million in the prior quarter.
Across five years, Intangibles topped out at $9.6 million in Q2 2025 and bottomed at $21000.0 in Q4 2023.
Historically, Intangibles has averaged $2.4 million across 4 years, with a median of $142500.0 in 2021.
Annual changes were most pronounced in 2021 — Intangibles dropped 19.5% — and 2023, when it tumbled 75.29%.
HUTCHMED (China)'s Intangibles stood at $163000.0 in 2021, then tumbled by 47.85% to $85000.0 in 2022, then sank by 75.29% to $21000.0 in 2023, then surged by 42476.19% to $8.9 million in 2025.
Business Quant data shows HCM's Intangibles at $8.9 million in Q4 2025, $9.6 million in Q2 2025, and $21000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.45 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	918.00 Mn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	21.28 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	13.68 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	2.23 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.20 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	1.12 Bn
10	HUTCHMED (China)	2.18 Bn	2.18 Bn	-	-

Download Data